How is Regeneron Pharmaceuticals (REGN) doing?

Regeneron Pharmaceuticals is a company in the biotechnology industry, based in Tarrytown, NY, worth $76.9B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Weak

Regeneron Pharmaceuticals shares are up 32% over the past year, 14 points ahead of the S&P 500. Its type is Speculative Pop. Among large US stocks and funds it ranks in the 78th percentile on market beat, the 5th on staying power and the 36th on business growth. It appears on 6 of our dashboards.

$746.54+32% in a yearWorth $76.9B

Compare with LLY · ABBV · AMGN · BMY · MRK · AZN · ALNY · BIIB · GILD · MRNA · VRTX

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

REGN against the S&P 500, past year

$100 a year ago. Regeneron Pharmaceuticals +32%, the S&P 500 +16%.

REGNS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Speculative Pop

BeatingErraticSlowingBought

Beating the market with buyers piling in, but erratically, and its business growth trails most.

NovDecJanFebMarAprMayJunJulAugSepNow

Speculative Pop since Apr; Falling Knife before that.

Also Speculative Pop (69 in all): MTD · TMO · RPRX · DVA · BMY · BIO

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

REGN, past year+32%23 of 86 in the group

Rest of the group+20%equal-weighted

S&P 500+16%past year

Regeneron Pharmaceuticals is +32% over the past year, against +20% for the rest of the group and +16% for the S&P 500. It ranks 23rd of 86 in Health care.

REGNRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsLLY Lilly (Eli)+39%ABBV AbbVie+20%AMGN Amgen+41%BMY Bristol Myers Squibb+33%MRK Merck &+69%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Regeneron Pharmaceuticals typically moves 2.7% in a day, about usual for it, and it swings less than 62% of large US stocks.

Typical day2.7%about $20.41 a share

Its usual2.8%about usual, 1.0× its year’s average

Against the S&P 5002.5×the index’s typical day is 1.1%

Unusual day±5.5%twice its typical day

Deepest fall, past year−26%now 12% below its high

In the S&P’s down weeks82%of the index’s fall, three years; beta 0.6

Typical daily move (ATR)Its year’s average 2.80%

REGN on our dashboards

Every question where Regeneron Pharmaceuticals appears, in the order of the home page, with its reading and place in that table. Select a question to open it with REGN highlighted. Select a column to sort.

Question	Reading	Place	Details
Which companies earn the most on their capital? Business quality	98Excellent	10 of 60	Return on capital >200% · Gross margin 85% · Cash margin 23%
Which companies are built to last? Business quality	79Durable	8 of 60	Steady margins 95 · Reliable cash 57 · Balance sheet 84
Which companies invest the most in research? Business quality	97Heavy	6 of 60	R&D / revenue 41.6% · R&D a year $6.5B · R&D, 1Y +17%
Which stocks are cheaper than their rivals? Value	88Cheaper	51 of 60	P/E 18.5x · Rivals’ P/E 32.7x · Growth gap 0 pts
Which companies pay the most in stock? Dividends and buybacks	91Heavy	34 of 60	% of revenue 6.4% · A year $986.7M · % of cash flow 28%
Where is money flowing in? Who’s buying and selling	89Inflow	58 of 60	30 days 31 · 5 days 42 · Net buying +11%

Go deeper on Stox

REGN’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open REGN on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see REGN’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›LLY · Lilly (Eli) ›ABBV · AbbVie ›AMGN · Amgen ›BMY · Bristol Myers Squibb ›